TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05081245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ML-004 (IR)/(ER) tablet
Description: Participants will receive ML-004 once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ML-004 Placebo
Description: Participants will receive matching placebo once daily.
Study: NCT06267001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IV.
Study: NCT06398730

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
Study: NCT06445972

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/M\^2 IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/M\^2 IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2870
Description: 3 mg/kg or 4 mg/kg IV Infusion
Study: NCT05841394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
Study: NCT06452277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Tablet, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study: NCT06559176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PM359
Description: Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
Study: NCT05429268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
Study: NCT06561217

Intervention type: OTHER
Intervention: Chart review
Description: Chart review

Intervention type: OTHER
Intervention: Chart review
Description: Chart review

Intervention type: OTHER
Intervention: Chart review
Description: Chart review
Study: NCT06051383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management
Description: patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months
Study: NCT06143891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Table-Route of administration:oral
Study: NCT05852652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis and aerobic exercise
Description: the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park
Study: NCT06077240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 2.4% Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with lower nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 5% Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with higher nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with lower nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with higher nicotine concentration.
Study: NCT06523608

Intervention type: OTHER
Intervention: Standard survillance protocol
Description: Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.

Intervention type: OTHER
Intervention: Stratified survillance protocol
Description: Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
Study: NCT05260073

Intervention type: DRUG
Intervention: Tirbanibulin
Description: Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
Study: NCT04924530

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Co-ingestion of maltodextrin with a high fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Co-ingestion of sucrose with a high fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Co-ingestion of lactose with a high fat meal
Study: NCT06447779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (CHO Cell)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NaCl solution Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
Study: NCT05511727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single versus double Foley's catheter in pre-induction cervical ripening
Description: The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single versus double Foley's catheter in pre-induction cervical ripening
Description: The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
Study: NCT06143891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Pharmaceutical form:Tablet-Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06070649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25 mg Diphenhydramine (5 min) + Normal Saline
Description: Infusion
Study: NCT06091865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Odronextamab will be administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered IV, or subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine will be administered IV as part of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
Study: NCT06486662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85-IN
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85-IN
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
Study: NCT06091865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
Study: NCT06524739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
Study: NCT06214507

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06345339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armour Thyroid
Description: Oral Capsule or Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armour Thyroid
Description: Oral Capsule or Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral Capsule
Study: NCT06454630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508
Description: Administered by single intravenous (IV) dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
Study: NCT05624450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Single IV dose of tozorakimab on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of matching placebo on Day 1.
Study: NCT05318898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetal protein
Description: Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal protein
Description: Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
Study: NCT05887882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
Description: The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
Description: The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
Description: The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Undergo placement of Ommaya reservoir

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Undergo placement of Ommaya reservoir

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Undergo placement of Ommaya reservoir

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06486662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85-IN
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85-IN
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
Study: NCT04279847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB057643
Description: INCB057643 dose escalation and dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB057643
Description: INCB057643 dose escalation and dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
Study: NCT06347315

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BrainXpert
Description: sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
Study: NCT06486662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
Study: NCT05326165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juzo Compression Sleeve and Glove
Description: Elasticized garment sized for arm and hand to create pressure to reduce swelling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Sleeve Sensor
Description: Small device embedded within compression sleeve garment collecting usage information
Study: NCT04804241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senicapoc
Description: 10 mg oral tablet
Study: NCT05798429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compassion education
Description: 6 weeks of compassion training
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT04804241

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Oral Tablet
Study: NCT06418880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID system with Remote Real-Time CGM
Description: The Omnipod 5 AID System is comprised of two components:~* Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology)~* Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Insulin Therapy + CGM
Description: This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days).~Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns.
Study: NCT04975555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
Study: NCT06281080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En-Bloc Resection of Bladder Tumours
Description: Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
Study: NCT05533866

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: APR-TD011
Description: APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.